Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)

Pharmasoft

Status and phase: Completed; Phase 2

Conditions: Primary Open-Angle Glaucoma (POAG)

Treatments: Drug: Mexidol; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06903156

MexidolPOAG2023

PHS-FOG-006-MEX-SOL-TAB (Other Identifier)

Details and patient eligibility

About

The present trial is planned to investigate and identify the best dosage of investigational drugs with respect to the treatment of open-angle glaucoma. Therefore, multiple dose regimens of the investigational drug versus placebo drug are anticipated.

Full description

Glaucoma is a widespread group of diseases, which are united by disorders of the hydrodynamics of the eye with increased intraocular pressure (IOP), development of glaucoma optic neuropathy (GON) and corresponding irreversible changes in the optic nerve and visual fields.

The number of glaucoma patients worldwide ranges from 60.5 to 105 million, more than 1 million glaucoma patients have been identified in Russia, but it is assumed that the true number of patients is twice as high. According to epidemiological analysis, primary open-angle glaucoma (POAG) is the most common glaucoma worldwide, accounting for 75% to 90% of all primary glaucoma.

The active substance of Mexidol (ethylmethylhydroxypyridine succinate) has a multitarget effect on a number of links in the pathogenesis of POAG and is characterised by a high degree of safety, which corresponds to the concept of multimodal and modulating therapy of GON in POAG.

Enrollment: 102 patients

Sex: All

Ages: 35 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of both sexes aged 35 to 75 years inclusive.
• Diagnosis of primary open-angle glaucoma stage II or III in both eyes.
• Intraocular pressure (IOP) compliance with ""target level"": tonometric IOP <21 mmHg in stage II, <19 mmHg in stage III, in both eyes.
• The patient's willingness and ability to fulfil the requirements of the protocol throughout the trial.
• Patients who signed informed consent to participate in the trial.
• For women with preserved reproductive potential, a negative pregnancy test and agreement to use adequate contraceptive methods throughout the trial.
• For men, agreement to adhere to adequate contraceptive methods for the duration of trial participation.

Exclusion criteria

• Individual intolerance or hypersensitivity to any of the components of the investigational medicinal products according to anamnesis data.
• Administration of nootropic, vasoactive drugs, neuroprotectants, antioxidants, metabolic drugs for 30 days prior to randomisation.
• The need to use medications that are prohibited in this trial.
• Primary open-angle glaucoma stage I or IV in at least one eye.
• Closed-angle glaucoma of at least one eye.
• The only eye.
• Diagnosis of primary open-angle glaucoma stage II or III in one eye only.
• Visual acuity less than 0.1 (with correction) in at least one eye.
• Presence of an active infectious-inflammatory process in at least one eye.
• Low reliability of SAP results in at least one eye due to the patient's condition/disease: presence of 20% or more false positive and/or false negative errors, large amplitude and frequency of gaze direction deviations.
• The "mean deviation" (MD) score for static automatic perimetry (SAP) is -20 decibels or worse in at least one eye.
• Surgical and/or laser interventions on at least one eyeball within 3 months prior to inclusion in the trial.
• Significant opacities of the optical media in at least one eye, preventing assessment of the efficacy of therapy, including: severe scarring of the cornea, cataracts, consequences of uveitis.
• Retinal detachment in at least one eye.
• Thrombosis of a central retinal vein or artery in at least one eye.
• Myopia with a length of the anteroposterior axis of the eyeball greater than 26 mm in at least one eye.
• Diabetic retinopathy and other eye conditions that may affect the assessment of therapy efficacy.
• Presence of a history or finding of clinically significant pathology on screening, including but not limited to those listed below: unstable angina pectoris within 3 months before inclusion in the trial; myocardial infarction within 3 months prior to inclusion in the trial; acute heart failure; severe arrhythmia requiring treatment with class Ia, Ib, Ic or III antiarrhythmic drugs; decompensation of chronic heart failure (according to the New York Heart Association classification) within 3 months before inclusion in the trial; uncontrolled arterial hypertension with systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at screening; brain injury, stroke or transient ischaemic attack within 6 months prior to screening; occlusive blood vessel diseases; stenosing blood vessel diseases resulting in significant ischaemia of the relevant blood supply area; metabolic disorders, including severe renal insufficiency (creatinine clearance less than 30 ml/min); severe hepatic insufficiency (ALT or AST level is at least 2 times higher than the upper limit of normal values); malignant diseases of any localization with duration of remission less than 5 years according to anamnesis; II or III degree respiratory failure; community-acquired pneumonia within 6 months prior to inclusion in the trial; severe and/or uncontrolled endocrine and metabolic disorders requiring continuous medication; type 1 diabetes mellitus; type 2 diabetes mellitus, with a disease duration of 5 or more years; gastrointestinal disorders in the phase of relapse or exacerbation and requiring continuous medication.
• Positive serological reactions for infections at screening: Human immunodeficiency virus (antibodies to HIV-1/2); Hepatitis B (surface antigen); Hepatitis C (antibodies to hepatitis C virus antigens); Syphilis (antibodies to Treponema pallidum).
• Presence of other ophthalmological, neurological, otolaryngological or systemic diseases that may be the cause of optic nerve damage.
• The presence of any other pathology that, in the opinion of the investigator, is a contraindication to the patient's participation in the trial (i.e. may adversely affect the patient's condition if he or she participates in the trial), may interfere with the conduct of the trial procedures, or affect the ability to interpret the results of the trial. In case of doubt, the investigator should consult with the trial medical monitor.
• Signs of a first detected disease/pathology at screening.
• Positive rapid test for IgM antibodies to SARS-CoV-2 and/or positive SARS-CoV-2 RNA using nucleic acid amplification techniques
• Current or history (two years prior to screening) of alcoholism, drug abuse, drug dependence and/or substance abuse.
• Mental, physical and other reasons that make it impossible to adequately assess one's behaviour and correctly comply with the conditions of the trial protocol, including a history of mental illness.
• Lack of willingness to co-operate on the part of the patient.
• Pregnancy and breastfeeding period. A positive pregnancy test in women of childbearing potential.
• Patient participation in another clinical trial within the last 30 days.
• Patient refusal to continue participation in the trial.
• A decision by the Investigator or Sponsor to exclude a patient from the trial due to a significant protocol deviation/protocol violation.
• A serious adverse event (SAE) or an adverse event that does not meet the criteria for seriousness, for which, in the opinion of the Investigator, further participation in the trial may be detrimental to the health or well-being of the patient, or for which withdrawal of the investigational therapy is necessary.
• The need for procedures and/or adjunctive therapy not authorized by the protocol of this trial.
• Allergic reaction or individual intolerance to the investigational drugs, requiring their cancellation.
• Non-compliance with the therapy regime (patient's adherence to treatment with tablet form of the drug goes beyond 80%-120%, parenteral therapy - 100%), non-adherence (loss of contact with the patient with subsequent non-appearance at the visit, violation of visit dates, etc.).
• Need for modification of topical hypotensive therapy.
• Occurrence during the trial of conditions/diseases specified in the inclusion criteria.
• Any patient condition that, in the reasonable judgement of the investigator, requires the patient to be excluded from the trial.
• Erroneous inclusion.
• Positive pregnancy test in a trial participant.
• Positive rapid test for IgM antibodies to SARS-CoV-2 and/or positive SARS-CoV-2 RNA using nucleic acid amplification techniques.
• Erroneous unblinding of trial subject's treatment group.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

102 participants in 3 patient groups, including a placebo group

Mexidol High

Active Comparator group

Description:

High dose of Mexidol (Mexidol IV 500 mg 1 time a day for 14 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 90 days) and standard therapy

Treatment:

Drug: Mexidol

Mexidol Low

Active Comparator group

Description:

Low dose of Mexidol (Mexidol IV 100 mg 1 time a day for 14 days, then Mexidol 125 mg 1 tablet 3 times a day for 90 days) and standard therapy

Treatment:

Drug: Mexidol

Placebo

Placebo Comparator group

Description:

Placebo and standard therapy according to a scheme similar to Mexidol groups

Treatment:

Other: Placebo